Navigation Links
Palomar Wins Two European Hair Removal Patent Opposition Hearings
Date:5/14/2009

documents related to the home-use, light-based hair removal field for women. In addition, Palomar has an exclusive development and license agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current expectations, plans, intentions, beliefs or predictions. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, including patent infringement lawsuits, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2008 and the Company's quarterly reports on F
'/>"/>

SOURCE Palomar Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast
2. Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms
3. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
4. Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology
5. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
6. Palomar Medical Technologies to Host Second Quarter 2008 Financial Results Conference Call and Webcast on July 31, 2008
7. Palomar Medical Reports Financial Results for Third Quarter 2008
8. Palomar Medical Technologies and Reliant Technologies Announce Launch of a Fractional Technology Licensing Program
9. Reliant Technologies, and Palomar Medical Technologies, Announce Launch of a Fractional Technology Licensing Program
10. Palomar Medical Technologies to Host Fourth Quarter and Year End 2008 Financial Results Conference Call and Webcast on February 5, 2009
11. Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Lipitor lawsuits ( http://www.thelipitorlawsuit.com/ ... patients to develop Type 2 diabetes continue to move ... U.S. District Court, District of South Carolina, Bernstein Liebhard ... September 12, 2014, discovery is underway and moving forward ... that Pfizer, Inc., the manufacturer of Lipitor, has produced ...
(Date:9/19/2014)... 2014 In partnership with Raw Beauty NYC, ... part of the project’s social media efforts. StudioPMG is honored ... re-define the perception of beauty as it applies to disabled ... idea by Shelly Baer and Vanessa Silberman, who wanted to ... and beautiful. Ginny Dixon, Wendy Crawford, Susan Solman and Sabrina ...
(Date:9/19/2014)... Fla. Researchers at Jacksonville,s campus of Mayo Clinic ... they say contributes to both overproduction of toxic protein ... as well as loss of communication between neurons ... Their study, in the online issue of ... specific defect with drugs "may rejuvenate or rescue this ...
(Date:9/19/2014)... states are passing legislation permitting or requiring schools to ... having a severe allergic reaction. Epinephrine auto-injectors are ... can lead to throat swelling, breathing difficulties, a steep ... In people with severe allergies to certain foods, such ... drugs, anaphylaxis can occur within moments of exposure to ...
(Date:9/19/2014)... and large protein complexes are notoriously difficult to study ... very difficult, if not impossible, to crystallize, but also ... The result is that when a structure can be ... reveals a mosaic-like spread of protein domains that sometimes ... Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3
... from 12 Days to 27 Hours , ... leading provider of Windows file server virtualization solutions, today ... for medical research and treatment, has deployed its AutoClone(TM) ... of its Windows data replication operations. Since its ...
... line to provide sun protection, laughs and college ... Today non-profit Cancer for College launches a ... All proceeds from the sunscreen sales will go ... in granting college scholarships to cancer survivors and ...
... COM,VANCOUVER, May 19 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: ... period under the Hart-Scott-Rodino Act for the collaboration and ... Merck affiliate for development and commercialization of vernakalant, an ... expired, and the agreement is now effective. , Under ...
... say the disease is no more dangerous than regular ... World Health Organization may declare a full-fledged swine flu ... has swept through Japan, a former WHO infectious disease ... occurring in a region outside North America, where a ...
... plating system offers zero-step locking mechanismHOFFMAN ESTATES, Ill., ... market introduction of the KINETIC-SL Dynamic Anterior Cervical ... from the U.S. Food and Drug Administration (FDA) ... cervical plating system and utilizes a ...
... DIEGO, May 19 /PRNewswire/ -- ... major advances in the development of their first-in-class, CK2 ... Wednesday, May 20th at 4:40 pm. William G. Rice, ... antitumor properties and tumor selectivity of CX-4945, the Company,s ...
Cached Medicine News:Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 2Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 3Health News:Children's Hospital Boston Deploys AutoVirt Solution to Increase Speed and Efficiency of Windows Data Replication 4Health News:Photos: Will Ferrell Sunscreen to Launch Just in Time for Summer 2Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 2Health News:Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective 3Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 2Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 3Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 4Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 5Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 6Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 7Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 8Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 9Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 10Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 11Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 12Health News:Spread of Swine Flu in Japan Could Raise WHO Alert to Highest Level 13Health News:Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference 2
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
(Date:9/19/2014)... BALTIMORE and CAMBRIDGE, Mass. ... Diagnostics Inc. (PGDx), a provider of advanced ... Blueprint Medicines , a leader in discovering and ... cancers, today disclosed the first-ever comprehensive genomic study ... and deadly cancer of the female reproductive system, ...
(Date:9/19/2014)... 19, 2014  PCI is pleased to announce ... is a leading provider of Clinical Trial Services ... Wales in the ... expands PCI,s presence in the UK/EU to support ... packaging, storage and distribution capacity, as well as ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... April 23, 2007 /PRNewswire-FirstCall/,Micromet, Inc. today announced ... collaboration with MedImmune, Inc. for the development,of ... validated tumor- associated antigen frequently expressed on,various ... 2007 Annual Meeting of the American Association ...
... 23, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced ... Linda University Medical Center showing,that one of ... an important role regulating the oxidative damage,induced ... alone or in combination with surgery,and chemotherapy ...
Cached Medicine Technology:Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 2Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 3Micromet Achieves Milestone in BiTE Research Collaboration with,MedImmune 4Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation 2Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role,Regulating the Oxidative Damage Induced by Ionizing Radiation 3